>> my question is why did CLTR sell at this point. <<
Strange deal. I like the scientists, those who I am familiar with, but CRXA resources always seem to get diverted to lame, disappearing stuff. I agree with Wilder.
Want any new blood for the portfolio?
Tax selling is hitting VPHM hard, current ask is 19 3/8. Cash in the bank is not theirs, but.... for a very small differential (currently less than $100M, I believe) between that cash and MC, one gets three anti-virals in humans.... pleconaril, HCV (progress recently recognized by Wyeth-Ayerst) and RSV. J.P. Morgan was selling yesterday at 20 3/8, not for the faint of heart at this moment. Another suggestion is TELK at ask 6 1/2. Recent IPO at 7, below estimated range of 9-11, it has struggled. I'm not nuts about the TAP in phase I, but I'd love to be wrong. Retained rights to all projects, all geographies for some. Lots of leverage, and what appears to be a good combichem process underlying it. |
